Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Sarepta Therapeutics (SRPT)

Sarepta Therapeutics (SRPT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,150,195
  • Shares Outstanding, K 104,990
  • Annual Sales, $ 2,198 M
  • Annual Income, $ -713,410 K
  • EBIT $ -697 M
  • EBITDA $ -658 M
  • 60-Month Beta 0.42
  • Price/Sales 0.95
  • Price/Cash Flow N/A
  • Price/Book 1.99

Options Overview Details

View History
  • Implied Volatility 81.95% (+2.83%)
  • Historical Volatility 105.02%
  • IV Percentile 23%
  • IV Rank 18.61%
  • IV High 193.83% on 07/24/25
  • IV Low 56.36% on 03/31/25
  • Expected Move (DTE 2) 0.59 (2.86%)
  • Put/Call Vol Ratio 0.26
  • Today's Volume 2,208
  • Volume Avg (30-Day) 4,392
  • Put/Call OI Ratio 0.85
  • Today's Open Interest 117,252
  • Open Int (30-Day) 119,930
  • Expected Range 19.89 to 21.07

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 27 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate 0.26
  • Number of Estimates 5
  • High Estimate 1.84
  • Low Estimate -0.71
  • Prior Year -3.84
  • Growth Rate Est. (year over year) +106.77%

Price Performance

See More
Period Period Low Period High Performance
1-Month
15.52 +31.92%
on 03/06/26
23.85 -14.13%
on 03/25/26
+3.72 (+22.20%)
since 02/27/26
3-Month
15.52 +31.92%
on 03/06/26
24.68 -17.02%
on 01/26/26
-1.64 (-7.41%)
since 12/26/25
52-Week
10.41 +96.64%
on 07/24/25
67.47 -69.65%
on 03/31/25
-49.93 (-70.91%)
since 03/28/25

Most Recent Stories

More News
Sarepta Announces First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1

In early clinical results, Sarepta’s αvβ6 integrin-targeted siRNA approach achieves high muscle concentrations without dose limiting toxicity for FSHD1 and DM1 ...

SRPT : 20.48 (+2.55%)
Sarepta Announces First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1

In early clinical results, Sarepta’s αvβ6 integrin-targeted siRNA approach achieves high muscle concentrations without dose limiting toxicity for FSHD1 and DM1 ...

SRPT : 20.48 (+2.55%)
Sarepta to Share First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that on Wed., March 25, 2026, at 8:30 am Eastern Time, the Company will host a webcast...

SRPT : 20.48 (+2.55%)
Sarepta to Share First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that on Wed., March 25, 2026, at 8:30 am Eastern Time, the Company will host a webcast...

SRPT : 20.48 (+2.55%)
Sarepta Provides Regulatory Update on AMONDYS 45® and VYONDYS 53®

– Following feedback from FDA, Company intends to submit supplemental new drug applications to FDA by the end of April 2026 requesting conversion to traditional approval

SRPT : 20.48 (+2.55%)
Sarepta Announces that Screening and Enrollment are Underway in ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne

- Approximately 25 non-ambulatory participants will receive sirolimus as part of the regimen in Cohort 8 of the ENDEAVOR study - The...

SRPT : 20.48 (+2.55%)
Sarepta Therapeutics Announces Call for Applications for the 9th Annual Route 79, The Duchenne Scholarship Program

– Applications for the 2026-2027 academic year will be accepted until May 15, 2026 – Scholarships will be awarded to up to 20 individuals...

SRPT : 20.48 (+2.55%)
Sarepta Therapeutics to Present New Long-Term and Safety Data Across Gene Therapy and Exon-Skipping Programs at 2026 Muscular Dystrophy Association Clinical & Scientific Congress

Several abstracts, including a late-breaking podium presentation and posters, bring forward accumulating long-term efficacy, safety and caregiver-reported insights that deepen understanding of dystrophin...

SRPT : 20.48 (+2.55%)
Sarepta Therapeutics: Q4 Earnings Snapshot

Sarepta Therapeutics: Q4 Earnings Snapshot

SRPT : 20.48 (+2.55%)
Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Developments

Net product revenues for the full year 2025 totaled $1,864.3 million, consisting of $965.6 million of PMO net product revenue and $898.7 million of ELEVIDYS net product revenue ...

SRPT : 20.48 (+2.55%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company that focuses on the discovery and development of RNA-based therapeutics targeting rare and infectious diseases. It concentrates on the development of exon-skipping drug candidates targeting Duchenne muscular dystrophy (DMD), a...

See More

Key Turning Points

3rd Resistance Point 21.61
2nd Resistance Point 21.11
1st Resistance Point 20.80
Last Price 20.48
1st Support Level 19.99
2nd Support Level 19.49
3rd Support Level 19.18

See More

52-Week High 67.47
Fibonacci 61.8% 45.67
Fibonacci 50% 38.94
Fibonacci 38.2% 32.21
Last Price 20.48
52-Week Low 10.41

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.